Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1990:33:655-60.
doi: 10.1007/978-3-642-74643-7_119.

Autologous bone marrow transplantation in acute myeloid leukemia in first remission: first Dutch prospective study

B Löwenberg  1 , W L van Putten, L F Verdonck, A W Dekker, G C de Gast, R Willemze, F E Zwaan, J Abels, P Sonneveld, J van der Lelie, et al.
Affiliations
Clinical Trial

Autologous bone marrow transplantation in acute myeloid leukemia in first remission: first Dutch prospective study

B Löwenberg et al. Haematol Blood Transfus. 1990.

Abstract

We have prospectively compared the values of autologous BMT (auto-BMT) and allogeneic marrow transplantation (allo-BMT) in patients (age 15-60 years) with acute myeloid leukemia (AML) who attained complete remission (CR) following remission-induction therapy. In 90/117 cases CR was reached. In 32 of those complete responders auto-BMT was undertaken and in 21 eligible cases HLA-matched allo-BMT. AML relapse was the predominant cause of failure after auto-BMT (17/32). The incidence of relapse after allo-BMT was 6/21. Patients treated with auto-BMT and allo-BMT have an overall survival of 37% and 66% at 3 years posttransplant (P = 0.05). Survival of the nongrafted complete responders is less than 10%. Allo-BMT in adult patients with AML in first complete remission provides a superior outcome when directly compared with the results of auto-BMT.

PubMed Disclaimer

MeSH terms

LinkOut - more resources